Enasidenib: An Oral IDH2 Inhibitor for the Treatment of Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a hematologic malignancy that affects predominantly older patients, with a median age of diagnosis around 67. Overall prognosis is poor; however, novel targeted therapies that can potentially improve outcomes in these patients have emerged in recent years. Mutations i...

Descripción completa

Detalles Bibliográficos
Autores principales: Myers, Rebecca A., Wirth, Scott, Williams, Sherry, Kiel, Patrick J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press 2018
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347084/
https://www.ncbi.nlm.nih.gov/pubmed/30719396

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347084/
https://www.ncbi.nlm.nih.gov/pubmed/30719396

Ejemplares similares